Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653109 | 0.86 | SRD5A2 (0.47) | STAT3PARP10SRD5A2LPAR1LPAR5 | |
| SCHEMBL4622938 | 0.81 | HTR7 (0.39) | CCKBRLMNAMAPT | |
| SCHEMBL5653525 | 0.78 | SRD5A2 (0.44) | STAT3LTA4HPARP10SRD5A2LPAR1 | |
| SCHEMBL27805475 | 0.76 | TRPM8 (0.46) | LMNAMAPT | |
| SCHEMBL5650382 | 0.75 | MEN1 (0.46) | LPAR1LPAR5MAPT | |
| SCHEMBL5651545 | 0.75 | MMP12 (0.44) | HDAC3LMNAMAPT | |
| SCHEMBL4623713 | 0.72 | TRPM8 (0.46) | PARP10LPAR1LMNA | |
| SCHEMBL5653519 | 0.72 | CYP1A2 (0.44) | HDAC3CCKBRMAPT | |
| SCHEMBL2246521 | 0.71 | HTR7 (0.40) | MCHR1LMNAMAPT | |
| SCHEMBL8431792 | 0.71 | EPHX2 (0.43) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | STAT3 3362/4885LTA4H 638/4885HDAC3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.